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Abstract
Background: During clinical development of the licensed Japanese encephalitis chimeric virus vaccine (JE-CV),
the neutralization capacity of vaccine-induced antibodies was assessed against the vaccine virus and against well
characterized wild-type (wt) viruses isolated between 1949–1991. We assessed whether JE-CV-induced antibodies
can also neutralize more recent wt Japanese encephalitis virus (JEV) isolates including a genotype 1 isolate.
Methods: Sera from 12–18 month-old children who received a single dose of JE-CV in a phase III study in Thailand
and the Philippines (ClinicalTrials.gov NCT00735644) were randomly selected and pooled according to neutralization
titer against JE-CV into eight samples. Neutralization was assessed by plaque reduction neutralization tests (PRNT50)
against three recent isolates from JEV genotypes 1 and 3 in addition to four JEV previously tested.
Results: Neutralization titers against the three recent JEV strains were comparable to those observed previously
against other strains and the vaccine virus. The observed differences between responses to genotype 1 and 3
viruses were within assay variability for the PRNT50.
Conclusions: The results were consistent with previously generated data on the neutralization of wt JEV isolates,
immune responses induced by JE-CV neutralize recently isolated virus from southeast (SE) Asia and India.
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Background
Japanese encephalitis (JE) is a mosquito-borne viral disease
that is seasonally endemic in many countries in Southeast
Asia, with three billion people living in endemic areas [1].
Although most infections are sub-clinical, JE infection can
cause febrile illness associated with central nervous system
inflammation [2].
JE is a vaccine-preventable disease and several vaccines
are currently in use [1,3,4]. A live, attenuated, JE chimeric
virus vaccine (JE-CV), developed by replacing the pre-
membrane and envelope coding sequences from the
yellow fever vaccine virus (strain 17D) genome with the
corresponding sequences from the JE SA14–14–2 virus
strain [5,6], was approved in 2010 by the Therapeutic
Goods Administration (TGA) in Australia and by the
Thai Food and Drug Administration, and is known as
IMOJEV™. In clinical development JE-CV was shown to
be safe and immunogenic in adults and children with
99% and more than 95% of recipients seroprotected
one month after the vaccination respectively [7,8].
JE virus (JEV), a member of the genus Flavivirus, is
considered to exist as a single serotype and four main
genotypes were identified initially on the basis of sequence
within the pre membrane (prM) gene region [9,10]. More
recently, the sequence of the envelope (E) gene region was
proposed and used to define JEV genotypes, and using
this method a fifth genotype was identified [11]. The
JEV neutralizing antibody response is considered to be
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the correlate of protection for JE vaccines, with a plaque
reduction neutralization 50% (PRNT50) titer of 1:10
defining the seroprotective threshold [12-14]. However,
PRNT50 assays are performed mostly using the vaccine
homologous virus [15,16], with neutralization responses
against wild-type JEV in general less well characterized,
perhaps unsurprising given the difficulty in isolating
JEV from clinical infections. It is noteworthy that all
licensed JE vaccines are based on genotype 3 viruses.
Assessing vaccine-induced neutralization responses against
circulating heterologous strains of JEV, particularly against
JEV genotype 1 which is now the dominant genotype
across parts of Asia, [17-19] provides a deeper under-
standing of a vaccine’s immunogenicity.
We previously demonstrated the ability of serum from
adults and children vaccinated with JE-CV to neutralize
heterologous wt JEV from genotypes 1–4 isolated between
1949 and 1991 [5,8]. Two recent publications with other
JE vaccines suggested that genotype 1 JEV are less well
neutralized than genotype 3 JEV [20,21]. We therefore
sought to further characterize the immunogenicity of
JE-CV by assessing neutralization against recent JEV
isolates, with emphasis on whether there are differences
between genotypes 1 and 3.
Methods
Serum pools from immunized toddlers
Sera were obtained from 12–18 month old children at
who had received a single dose of JE-CV in a phase III
study in Thailand and the Philippines (ClinicalTrials.gov
NCT00735644; [22]).
Positive and negative sample pools were created using
sera collected from these children on D28 post-vaccination
and pre-vaccination, respectively. The selection of individ-
ual serum samples for pooling was based on JEV neutraliz-
ing antibody titers determined in JE-CV PRNT50 assay
previously as part of the study [22]. Five different titer
categories were created for pooling: negative (titers <10,
one pool), low (titers 40–80, two pools) medium (titers
160–320, two pools), high (titers 640–2560, two pools),
and very high (titers >5120, one pool). The medium titer
sera pools most closely represent the response observed
in the original study population that had a geometric
mean titer (GMT) 95% confidence interval (CI) of 168–271
[22]. The other titer pools were created to assess the
relationship between the neutralization titer against wt
JEV, with the titer against the vaccine strain. Each pool
included 7–20 individual samples, all except two of
which were from children who were serologically JE-
naïve before vaccination (one subject in each of the low
titer pools had a JE-CV PRNT50 titer of ≥10). All except 3
of the samples were also serologically dengue-naïve before
vaccination (indicated by dengue PRNT titer ≥10 to at
least one serotype; one subject in one low titer pool, one
subject in one medium titer pool, and one subject in the
very high pool).
The Institutional Review Board of the Department of
Pediatrics at Phramongkutklao hospital, Bangkok, Thailand,
approved the protocol. The child’s parent or guardian pro-
vided signed informed consent as part of the original study
procedures.
JEV Viruses
Three isolates were obtained from the World Health
Organization (WHO) Flavivirus Diagnostics Reference
Laboratory for Asia at the Center for Vaccine Develop-
ment University of Mahidol, Thailand: JEV-SM1 a geno-
type 1 JEV isolated from a pig in Thailand, 2003, JEV-902/
97 a genotype 3 virus from a clinical case in Vietnam,
1997 and JEV-057434 another genotype 3 from a clinical
case in India, 2005.
Three well characterized reference viruses were used,
including two classified as genotype 3: Nakayama and
SA14-14-2, and one from genotype 1: TVP-8236. The
JE-CV vaccine virus, which is derived from SA14-14-2,
was also tested [23] (Table 1).
Neutralization tests
Three independent assay runs were performed for each
sera pool per virus by a single technician using the
method detailed below:
In brief, serial 10-fold dilutions of the serum pools were
mixed with a constant challenge dose of each respective
JEV (45–60 plaques per well) and inoculated in duplicate,
onto wells of a 6-well plate of confluent LLC-MK2 cells.
After adsorption, cell monolayers were overlaid with
carboxymethylcellulose (CMC)/neutral red and incubated
for several days. Plaques were then enumerated in each
well. The neutralizing antibody titer was calculated and
expressed as the reciprocal serum dilution (1/dil) reducing
the mean plaque count by 50% as calculated by probit
analysis.
Statistical methods
GMTs were calculated for each sample against the JEV
using the three independently generated results per sample
per JEV. The calculation of GMT from the 3 independent
sample runs was performed to minimize any impact of
assay variation on interpretation of the JEV neutralization.
Normal assay variation is considered to be approximately
one 2-fold difference in titer.
The seven JEV were ranked for neutralization sensitivity
within each sample pool using GMT.
Results
Geometric mean titers
Each of the serum pools were tested in three independent
assay runs in the respective wild type JEV and the GMT of
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Table 1 JEV used in JEV PRNT50 testing
JEV Genotype Country of origin Year of origin Virus origin Passage history of virus Accession number
JEV-057434 3 India 2005 Human 2 passages in mosquito cell lines; 3 passages in Vero cells [Genbank:EF623988.1]
JEV-SM1 1 Thailand 2003 Pig 2 passages in mosquito cell lines; 3 passages in Vero cells [Genbank:DQ087971.1]
JEV-902/97 3 Vietnam 1997 Human 1 passage C6/36 cells; 1 passage in suckling mouse;
3 passages in LLC-MK2 cells
[Genbank:JQ390453.1]
TVP-8236 1 Korea 1991 Culex tritaeniorhynchus 6 passages in mosquito cell lines; 6 passages in Vero cells Not available
SA14-14-2 3 China 1954 Derived from SA14 isolated in
Culex pipiens mosquitoe
Passages in mouse brain, PHK cells, mouse spleen, mouse
skin, hamster spleen, with multiple intermediate plaque
purifications in CEF [24]; 3 passages in Vero cells
[Genbank:AF315119.1]
Nakayama 3 Japan 1935 Human 11 passages in suckling mouse; 4 passages in Vero cells [Genbank:EF571853.1]
JE-CV 3 Chimeric Virus, YF 17D with Envelope sequence from SA-14-14-2 [23] 5 passages in Vero cells Not applicable
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the seven positive samples (+/− standard deviation) is pre-
sented in Figure 1. All seven strains were neutralized by
pools of the JEV antibody-positive samples, whereas none
were neutralized by the pooled JEV antibody-negative pre-
vaccination samples (Table 2).
In each pool, GMTs against the seven strains were
similar and generally within one 2-fold difference of each
other (Figure 1 and Table 2). For example, the two low
level JEV Ab positive samples showed titers between
39–182 and 59–113; the medium titer samples 98–361
and 126–388; high titer samples from 155–841 and
299–766; and very high titer pool from 346–2865 for
the seven JEV strains, respectively. Overall, the results
for each individual sample are within the expected assay
variability for a functional assay, though the very high titer
sample shows slightly higher variability.
The neutralization titers against the recent JEV were
comparable to those against the vaccine virus and the
non-contemporary wild-type JEV.
Genotype 1 and 3 strains were also neutralized with
similar titers: titers of 160–167 against genotype 1 and
163–369 against genotype 3 were observed in the medium
titer pool. GMTs against the vaccine virus ranged from
200–388, and against the non-contemporary wild-type
strains ranged from 157–344 and 126–186 (Table 2).
GMTs against the vaccine virus was within the range
of titers observed to the wild-type JEV in all sample
pools, except in the very high titer pools where the
GMT to vaccine virus was 3–8 fold higher.
Relative neutralization sensitivities
Since the challenge dose of the virus used in the PRNT
was similar for each virus (average input plaque count
per well of 45–60), the relative neutralization sensitivity
of the six different JEV and the vaccine virus was
assessed. The sample neutralizing antibody GMTs were
used to rank the JEV within each sample pool and to
generate an average rank (Table 3). In general the differ-
ences in neutralization titers within samples to each JEV
were not marked, and not statistically significant as
the 95%CIs of the overall GMTs overlap. A trend for
JE-057434, JE-CV, and JE Nakayama from genotype 3
as the most neutralization sensitive was observed, i.e.,
samples had higher titers against these JEV versus the
other JEV tested. The two genotype 1 JEV were in the
middle of this ranking, and SA14-14-2, an attenuated
strain derived from a genotype 3 JEV and donor of the
prM and E sequences of the JE-CV vaccine strain, was
observed to be the least sensitive to neutralization.
Discussion
The assessment of vaccine immunogenicity is critical as
a surrogate for assessment of clinical efficacy [13]. The
immunogenicity of JE vaccines are usually assessed in
terms of neutralizing antibodies against the vaccine
virus or a homologous virus [15,16,22], however it is
also important to characterize the response against
heterologous circulating JEV. This study extends previ-
ous work, that documented the antibody responses to a
reference panel of wild-type JEV [5,8], by showing that
pooled sera from toddlers vaccinated with JE-CV also
neutralize recently isolated wild-type virus, including
genotype 1 virus [17-19]. Virus used in our studies were
obtained from pig, mosquito and clinical infections in
Vietnam, Thailand and India between 1997–2005. Other
authors have assessed the ability of vaccine-induced anti-
bodies to neutralize JEV obtained between 1935–1984
[23], with some more recent studies using JEV from 2002
[20] and 2009 [21].
Consistent with the classification of JEV viruses as a
single serotype, we observed no marked differences in
neutralization sensitivity between recent versus older
isolates, and saw that the highest level of neutralization
response was against the recent, genotype 3 isolate, JE-
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Figure 1 Geometric mean titers for the sera pools against the different JEV.
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Table 2 GMTs of sera pools tested with different JEV
Pool details JEV PRNT50 neutralization results
Sample no. Pooled sera samples titer categorya JEV-SM1b JE-057434b JE-902/97b TVP-8236c JE-CVc SA14-14-2c JE Nakayamac Sample overall GMT
1 Low 84 (68–103) 165 (64–423) 94 (83–106) 130 (71–240) 65 (46–91) 39 (8–181) 182 (62–533) 96 (74–126)
2 Low 98 (86–111) 108 (45–258) 90 (65–125) 82 (70–96) 112 (54–231) 59 (41–84) 113 (51-252) 93 (81–106)
3 Medium 167 (84–332) 361 (235–554) 181 (114–286) 157 (97–254) 200 (111–360) 98 (41–232) 344 (136–872) 197 (158–246)
4 Medium 160 (84–305) 369 (225–604) 163 (124–214) 148 (80–276) 388 (167–899) 126 (81–196) 186 (81–429) 200 (161–249)
5 High 276 (150–508) 841 (380–1860) 155 (85–286) 253 (164–391) 780 (557–1092) 159 (71–355) 404 (192–851) 333 (244–456)
6 High 749 (539–1040) 766 (359–1634) 522 (419–649) 523 (348–788) 520 (205–1319) 299 (138–649) 474 (298–753) 529 (448–623)
7 Very high 517 (368–728) 1023 (600–1743) 346 (269–446) 638 (455–895) 2865 (1660–4945) 699 (609–803) 902 (788–1034) 801 (598–1074)
8d Negative <10 <10 <10 <10 <10 <10 <10 <10
JEV Overall GMT 218 (152–313) 397 (271–584) 183 (138–244) 214(154–300) 351 (201–613) 138 (89–214) 302 (218–418) 243 (209–282)
GMTs are presented in bold font with 95% confidence intervals in parentheses.
aResults from original study testing using JE-CV PRNT assay at Focus Diagnostics Ltd., US [22]; low = titer range 40–80, medium = titer range 160–320, high = titer range 640–2560, very high = titer range >5120.,
negative = <10.
bRecent JEV isolate.
cJEV isolate tested in previous clinical trials [5,8].
dSample 8 was not used in calculating overall (sample/JEV) GMT.
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057434. We also saw no difference in the capacity to
neutralize genotype 1 and genotype 3 viruses with titers
generally within 2-fold of each other, confirming our pre-
vious observations both at 28 days and 6 months after
vaccination [5,8]. It was observed that the neutralization
response against the homologous vaccine strain, JE-CV,
trended higher than the parental strain SA14-14-2. This
may relate to the different cell lines used to passage the
two viruses (Table 1). In another study, sera from indi-
viduals vaccinated with SA14-14-2 neutralized virus
from genotype 1 with titers that were similar to or 1–4-
fold lower than titers against genotype 3 viruses [25].
Our findings with serum collected after vaccination
with JE-CV contrast with those in recent reports that
used some of the same JEV strains [20,21]. With sera
from subjects vaccinated with an inactivated Vero cell
derived vaccine, there was a 10-fold difference in titers
between assays performed with a genotype 1 virus,
compared with the vaccine-homologous genotype 3 virus
[20]. Similarly, in a separate study of a mouse brain derived
vaccine titers were 3–8-fold lower to genotype 1 compared
with the genotype 3 vaccine-homologous strain, and 2-3-
fold lower than a heterologous genotype 3 strain [21].
It is unclear why differences in relative neutralization of
genotype 1 JEV have been observed. JEV neutralization is
not necessarily expected to correlate with genotype given
that a single serotype of JEV exists, and that identification
of genotypes 1 and 3 was based initially upon the prM
gene [9,10], whereas neutralization is mediated primarily
through the E protein [26]. However, some antigenic
differences have been observed between genotype 1 and 3
strains using JEV Env specific mAb, although the majority
of mAb tested bound to strains from both genotypes [27].
Another possibility may relate to methodological differ-
ences in either the laboratory culture of JEV or the sero-
logical assays or both, although this is not apparent in the
case of one of these studies as the same assay and some of
the same viruses were used [20]. Furthermore, in our data
a relationship between the number of laboratory passages
and neutralization sensitivity across these JEV is not ap-
parent (data not shown).
One factor that does differ between these studies is
the type of vaccine given: neutralizing responses in-
duced by live attenuated vaccines (JE-CV and SA14-14-
2) were not inferior against genotype 1 virus compared
to homologous virus [5,8,25], while responses induced
by inactivated vaccine were [20,21]. However, this contrasts
somewhat to the first inactivated JEV vaccines that were
shown to neutralize heterologous JEV isolates, and also
provide protection against disease in Taiwan and Thailand
reviewed in [28].
The similar levels of neutralization seen after vaccin-
ation with JE-CV in our study suggests that the recent
emergence of genotype 1 JEV in replacement of geno-
type 3 [17,18,29,30], and the continued observation of
isolates with varied sequences [31], are not necessarily a
cause for concern. Epidemiological data do not indicate
a noticeable increase in JE disease that presumably would
be attributable to genotype 1 [17,18,29]. However given
the conflicting neutralization findings in the literature, the
epidemiology of JEV and any genotype associations should
continue to be monitored [19,30].
Conclusions
Immune responses induced in toddlers by vaccination with
the licensed JE-CV vaccine were able to neutralize recent
wild-type viruses circulating in SE Asia and India, with
similar titers compared to the vaccine strain and other
wild-type strains. This finding is reassuring given the
constant evolution of the virus and of its geographic
distribution in Asia.
Abbreviations
CMC: Carboxymethylcellulose; E: Envelope; JE: Japanese encephalitis; JE-CV: JE
chimeric virus; JEV: JE virus; prM: Pre membrane; PRNT50: 50% plaque reduction
neutralization; SE: Southeast; TGA: Therapeutic goods administration;
WHO: World Health Organization; wt: Wild-type; 1/dil: Reciprocal dilution.
Table 3 Ranking for JEV neutralization sensitivity within each sera pool
Sample no. JEV-SM1 JE-057434 JE-902/97 TVP-8236 JE-CV SA14-14-2 JE Nakayama
1 5 2 4 3 6 7 1a
2 4 3 5 6 2 7 1
3 5 1 4 6 3 7 2
4 5 2 4 6 1 7 3
5 4 1 7 5 2 6 3
6 2 1 4 3 5 7 6
7 6 2 7 5 1 4 3
8b N/A N/A N/A N/A N/A N/A N/A
Average rank 4.4 1.7 5.0 4.9 2.9 6.4 2.7
Average rank is presented in bold font.
aRanking performed from 1 being the most neutralization sensitive (i.e. the highest neutralization titers) to 7 being the lowest.
bN/A – Not applicable, sample 8 was negative for all virus strains and was not used in the ranking.
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